Isis Alicaforsen Crohn’s Disease Failure Switches Focus To Ulcerative Colitis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Isis re-focusing alicaforsen Phase III development on ulcerative colitis after failure in Crohn’s disease. The antisense agent did not show difference in clinical remission versus placebo in two Phase III Crohn’s trials. Results from recently completed Phase II UC studies show potentially greater duration of response than standard of care, firm says